Demographics | Â |
 n | 10 |
 Median age (IQR), years | 47 (26–69) |
 < 18 years | 20% (2/10) |
 Male gender | 30% (3/10) |
 Days from symptom onset to admission | n = 3 on day 1, n = 1 on day 2 |
Clinical presentation | |
 Encephalitis | 50% (5/10) |
 Stroke-like | 30% (3/10) |
 Meningitis | 20% (2/10) |
Diagnostic testing | |
 HSV-1 (PCR of CSF) | 20% (2/10) |
 HSV-2 (PCR of CSF) | 50% (5/10) |
 HSV not distinguished (PCR of CSF) | 20% (2/10) |
 PCR negative for HSV-1 (CSF) but antibody rise | 10% (1/10) |
CSF findings | |
 Pleocytosis (> 4 cells/μl) | 100% (10/10) |
 Median cell count# (cells/μl, IQR, n = 10) | 42 (15–199) |
Neuroimaging | |
 Ischemia on first brain imaging | 50% (5/10) |
 Hemorrhage on first imaging, ischemia later | 20% (2/10) |
 Presence of loco-typico HSV lesion | 10% (1/10) |
 Evidence for vasculitis | 63% (5/8) |
 Affected vessels | |
  Small-sized | 0% |
  Large-sized | 100% (5/5) |
 Affected areas of circulation | |
  Anterior | 30% (3/10) |
  Posterior | 20% (2/10) |
  Anterior and posterior | 50% (5/10) |
 Distribution of lesions | |
  Single | 10% (1/10) |
  Multiple | 90% (9/10) |
Intervention | |
 Steroid treatment | 40% (4/10) |
Outcome | |
 Good outcome (mRS 0–2) | 56% (5/9) |
 Unfavorable outcome (mRS 3–5) | 44% (4/9) |
 Fatality | 0% |